Literature DB >> 15927434

Analytical methods for the quantification of ibandronate in body fluids and bone.

Richard Endele1, Heiner Loew, Frieder Bauss.   

Abstract

The accurate determination of bisphosphonate levels in bone and biological fluids is important in both clinical and pharmacological/toxicological studies. Ibandronate is a potent nitrogen-containing bisphosphonate containing a tertiary amine group, which does not easily form chromophore derivatives that can be detected by UV light or fluorescence emissions. The current report describes the methodology and validation of a GC-MS assay for ibandronate in serum/plasma and urine, a similar, modified GC-MS method for measurement of bone ibandronate levels, and an ELISA for ibandronate determination in serum/plasma. The range of quantification for the GC-MS was 1-100 ng/ml and 2-7500 ng/ml in plasma or serum and urine, respectively, and 50-1600 pg/ml (potentially 10-320 pg/ml depending on sample size) for the ELISA in plasma or serum. These assays were comparable. The practical application of the assays in preclinical and clinical studies is briefly reviewed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15927434     DOI: 10.1016/j.jpba.2005.03.020

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

1.  Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat.

Authors:  Frieder Bauss; Thomas Pfister; Socrates Papapoulos
Journal:  J Bone Miner Metab       Date:  2008-07-04       Impact factor: 2.626

2.  The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties.

Authors:  Kiyohiko Nakai; Masato Tobinai; Junko Hashimoto; Satofumi Iida; Takehiko Kawanishi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-05       Impact factor: 2.441

3.  A novel micro-extraction strategy for extraction of bisphosphonates from biological fluids using zirconia nanoparticles coupled with spectrofluorimetry and high performance liquid chromatography.

Authors:  Nadereh Rahbar; Ladan Nazernezhad; Maryam Asadinezhad; Zahra Ramezani; Maryam Kouchak
Journal:  J Food Drug Anal       Date:  2018-04-05       Impact factor: 6.157

4.  Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis.

Authors:  Frieder Bauss; Ralph C Schimmer
Journal:  Ther Clin Risk Manag       Date:  2006-03       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.